CAV1 and triple-negative breast carcinoma: From the above, it could be seen that the abnormal expression of ASNS, LAMP2, CAV1, DPP4 in triple-negative breast cancer and HELLS, TF, ZFP69B in breast cancer have not been experimentally verified, and these genes could exist as potential treatment biomarkers of TNBC.